INTRODUCTION AND OBJECTIVES:
We previously reported the incidence of urologic-induced Clavien grade III complications of Prophylactic Ureteral Localization Stents (PULSe) is estimated at 2%. Conclusions of this study raised the possibility of mandatory guidewire utilization prior to all PULSe placement, as this was not obligatory in the initial series. As a quality improvement project, we sought to compare a modification of technique, mandatory use of guidewire, prior to PULSe placement to reduce urologic-induced complications in this patient cohort. Moreover, we performed a systematic review of the literature to determine the overall incidence of urologic-induced complications in patients undergoing PULSe placement.
METHODS: We performed a retrospective review of all patients who underwent cystoscopy and PULSe placement at the time of General Surgical Procedure over a 12-month period. We compared this patient cohort to our prior cohort from July 2013 to June 2014 with the following variables: age, BMI, ASA score, pre-operative creatinine, post-operative creatinine, pre/post-operative creatinine difference, and Clavien III urologic-induced complications. We then performed a literature review from 1985-2018 using the following search terms: 'prophylactic ureteral stent' and 'localization stent'. Of the 145 studies reviewed, 14 publications met our inclusion criteria of PULSe prior to surgical procedure for the purpose of ureteral localization.
RESULTS: In a current institutional series, 132 patients with a mean age and BMI of 55.78 (18-89) and 27.02, respectively, underwent bilateral PULSe placement with mandatory use of guidewire. No Clavien III complications were encountered in the contemporary cohort, compared to the prior incidence of 2% (p<0.001) Moreover, postoperative creatinine and pre/post-procedural creatinine difference also favored the contemporary cohort (p<0.022 and p<0.003, respectively). Review of literature and complication profile can be seen in Table 1 is a significant complication after radical cystectomy (RC) with rates estimated between 10 and 30%. Enhanced Recovery after Surgery (ERAS) focuses on interventions to improve return of bowel function and decrease hospital length of stay (LOS) but few address SSIs directly. There is early evidence in general surgery that incisional negative-pressure wound therapy (iNPWT) may decrease wound related complications.
METHODS: As part of our RC ERAS pathway, we employ iNPWT during abdominal closure. After closure of the fascia and deep dermal layers of the abdominal wall, an iNPWT dressing is applied over a protective antimicrobial non-adherent contact dressing. The dressings are changed after postoperative day 3 and removed prior to discharge. We retrospectively reviewed patients undergoing RC with urinary diversion by a single-surgeon from 2014-2017. We compared 90 day SSIs, Surgical Site Occurrences (SSOs), and readmissions between iNPWT and standard skin staple closure. SSOs were defined as SSI, seroma, or superficial wound dehiscence.
RESULTS: We identified 158 (104 iNPWT, 54 standard) patients from 2012 to 2017. There was no difference in terms of age (70.5 vs 69.7 years, p [ 0.62), BMI (28.2 vs. 27.9 kg/m2, p [ 0.81), or diabetes (24.0% vs 16.7%, p [ 0.29) . The rates of SSI/SSOs were 9.7% and 19.0%, respectively. The readmission rate was 21.5% with 4.4% readmitted for SSI. The iNPWT group had a significantly lower rate of SSIs (5.8% vs. 16.7%, p [ 0.03) and SSOs (11.5 vs. 33.3%, p <0.01). There was no difference between the two groups for readmission (21.1 vs. 22.2%, p [ 0.5) or SSI-specific readmission (3.9% vs. 5.6%, p [ 0.62). On multivariable analysis, female patients and obese patients were more likely to experience SSI/SSOs. iNPWT significantly protected against both SSI (OR 0.89, 95% CI: 0.81-0.98) and 90-day SSO (OR 0.77, 95% CI: 0.68-0.87) but not readmissions (OR 1.01, 95% CI: 0.87-1.18) or SSI specific readmission (OR 0.97, 95% CI: 0.91-1.04).
CONCLUSIONS: Prophylactic iNPWT is feasible after RC with urinary diversion with and shows a modest decrease in 90 day SSIs and SSOs. iNPWT assisted wound closure should be as a component of RC ERAS protocols.
